Inhibition of the Rise in FFA by Acipimox Partially Prevents GH-Induced Insulin Resistance in GH-Deficient Adults
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To test the hypothesis that GH-induced insulin resistance is mediated by an increase in FFA levels we assessed insulin sensitivity after inhibiting the increase in FFA by a nicotine acid derivative, Acipimox, in nine GH-deficient adults receiving GH replacement therapy. The patients received in a double blind fashion either Acipimox (500 mg) or placebo before a 2-h euglycemic (plasma glucose, 5.5 +/- 0.2 mmol/liter) hyperinsulinemic (serum insulin, 28.7 +/- 6.3 mU/liter) clamp in combination with indirect calorimetry and infusion of [3-(3)H]glucose. Acipimox decreased fasting FFA by 88% (P = 0.012) and basal lipid oxidation by 39% (P = 0.015) compared with placebo. In addition, the insulin-stimulated lipid oxidation was 31% (P = 0.0077) lower during Acipimox than during placebo. Acipimox increased insulin-stimulated total glucose uptake by 36% (P = 0.021) compared with placebo, which mainly was due to a 47% (P = 0.015) increase in glucose oxidation. GH induced insulin resistance is partially prevented by inhibition of lipolysis by Acipimox.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of fat-free mass using bioelectrical impedance measurements of the human body
Lukaski, H., Johnson, P., Bolonchuk, W., & Lykken, G. (1985) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/41.4.810 · Cited by 1,896
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
GROOP, L. C., SALORANTA, C., SHANK, M., BONADONNA, R. C., FERRANNINI, E., & DEFRONZO, R. A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-96 · Cited by 312 · cited 1×
“This could partially be a consequence of the study design, as the Km for insulin-stimulated glucose uptake is lower than that for nonoxidative glucose uptake; the insulin levels attained during the clamp were submaximal for stimulation of nonoxidative glucose metabolism (22).”
BackgroundSelf-citation
Cited by
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1
LeRoith, D., & Yakar, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0427 · Cited by 344
“Definitive evidence of the role of FFAs in GH-mediated insulin resistance was obtained in clinical studies in which the effects of exogenously administered GH on insulin resistance were abrogated by acipimox, an inhibitor of lipolysis”
BackgroundInsulin-like growth factor-1 deficiency and metabolic syndrome
Aguirre, G. A., De Ita, J. R., de la Garza, R. G., & Castilla-Cortazar, I. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0762-z · Cited by 295
Sun, Y., Butte, N. F., Garcia, J. M., & Smith, R. G. (2008) · Endocrinology · doi:10.1210/en.2007-0271 · Cited by 274
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Metadata
- Authors
- Segerlantz, M.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-12-01
- Volume
- 86
- Issue
- 12
- Pages
- 5813-5818
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2108491393
- Cited by
- 61
- References
- 3
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.